Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02542384 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery
A Phase 2 study, sponsored by Cara Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 451
- Enrollment target
NCT02542384 is a Phase 2 study that has completed, run by Cara Therapeutics. The registered enrollment target is 451 participants.
The verdict
NCT02542384, a Phase 2 study, has completed, sponsored by Cara Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 451 participants
- Enrollment target
Study Summary
The study schedule is comprised of a 14-day Screening Period, a treatment period and an observation period. All eligible subjects will be randomized into one of 3 treatment groups (1 of 2 dose levels or matched placebo). Study drug CR845 will be administered intravenously prior to surgery, and at specific time intervals post surgery. Additional rescue pain and anti-nausea medication will be made available. Post surgical changes in pain intensity, nausea and vomiting will be assessed.
Interventions
- DRUG Placebo IV
- DRUG CR845 IV 1 mcg/kg
- DRUG CR845 IV 0.5 mcg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 451 participants |
| Start Date | 2015-09 |
| Est. Completion | 2018-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02542384
The ClinicalTrials.gov registry entry for NCT02542384 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 451 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cara Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo IV is the first listed.
NCT02542384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02542384 about?
NCT02542384 is a clinical study titled "A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery". The study schedule is comprised of a 14-day Screening Period, a treatment period and an observation period. All eligible subjects will be randomized into one of 3 treatment groups (1 of 2 dose levels or matched placebo). Study drug CR845 will be administered intravenously prior to surgery, and at sp...
What is the current status of trial NCT02542384?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 451 participants. The study started on 2015-09. Estimated completion is 2018-06.
What interventions are being tested in trial NCT02542384?
The interventions under investigation include: Placebo IV (DRUG), CR845 IV 1 mcg/kg (DRUG), CR845 IV 0.5 mcg/kg (DRUG).
Who is sponsoring clinical trial NCT02542384?
This trial is sponsored by Cara Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.